NasdaqGM:ITRM

Stock Analysis Report

Executive Summary

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States.

Snowflake

Fundamentals

High growth potential and slightly overvalued.

Share Price & News

How has Iterum Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-0.6%

NasdaqGM:ITRM

-1.8%

US Pharmaceuticals

-1.0%

US Market


1 Year Return

-22.3%

NasdaqGM:ITRM

-6.6%

US Pharmaceuticals

-0.4%

US Market

ITRM underperformed the Pharmaceuticals industry which returned -6.6% over the past year.

ITRM underperformed the Market in United States of America which returned -0.4% over the past year.


Share holder returns

ITRMIndustryMarket
7 Day-0.6%-1.8%-1.0%
30 Day1.2%-3.5%-3.3%
90 Day-3.8%-3.8%0.8%
1 Year-22.3%-22.3%-4.3%-6.6%1.9%-0.4%
3 Yearn/a7.9%0.6%39.4%30.4%
5 Yearn/a22.9%10.0%54.2%37.1%

Price Volatility Vs. Market

How volatile is Iterum Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Iterum Therapeutics undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Iterum Therapeutics's share price is below the future cash flow value, and at a moderate discount (> 20%).

Iterum Therapeutics's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

Iterum Therapeutics is loss making, we can't compare its value to the US Pharmaceuticals industry average.

Iterum Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Iterum Therapeutics, we can't assess if its growth is good value.


Price Based on Value of Assets

Iterum Therapeutics is overvalued based on assets compared to the US Pharmaceuticals industry average.


Next Steps

Future Growth

How is Iterum Therapeutics expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

37.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Iterum Therapeutics's revenue is expected to grow significantly at over 20% yearly.

Iterum Therapeutics's earnings are expected to grow significantly at over 20% yearly.

Iterum Therapeutics's revenue growth is expected to exceed the United States of America market average.

Iterum Therapeutics's earnings growth is expected to exceed the United States of America market average.

Iterum Therapeutics's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Iterum Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Iterum Therapeutics performed over the past 5 years?

-115.5%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Iterum Therapeutics does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.

Unable to compare Iterum Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Iterum Therapeutics's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Iterum Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Iterum Therapeutics has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Iterum Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Iterum Therapeutics's financial position?


Financial Position Analysis

Iterum Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Iterum Therapeutics's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Iterum Therapeutics's level of debt (58.1%) compared to net worth is high (greater than 40%).

Unable to establish if Iterum Therapeutics's debt level has increased without past 5-year debt data.


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 4.2x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Iterum Therapeutics has less than a year of cash runway based on current free cash flow.

Iterum Therapeutics has less than a year of cash runway if free cash flow continues to grow at historical rates of 61.1% each year.


Next Steps

Dividend

What is Iterum Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Iterum Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Iterum Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Iterum Therapeutics has not reported any payouts.

Unable to verify if Iterum Therapeutics's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Iterum Therapeutics has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Iterum Therapeutics's salary, the management and board of directors tenure and is there insider trading?

3.8yrs

Average management tenure


CEO

Corey Fishman (54yo)

3.8yrs

Tenure

US$1,757,007

Compensation

Mr. Corey N. Fishman has been the Chief Executive Officer of Iterum Therapeutics Ltd since November 2015 and serves as its President. Mr. Fishman served as the Chief Operating Officer and Chief Financial O ...


CEO Compensation Analysis

Corey's remuneration is higher than average for companies of similar size in United States of America.

Corey's compensation has increased whilst company is loss making.


Management Age and Tenure

3.8yrs

Average Tenure

54yo

Average Age

The tenure for the Iterum Therapeutics management team is about average.


Board Age and Tenure

3.0yrs

Average Tenure

54yo

Average Age

The tenure for the Iterum Therapeutics board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyUS$62,88704 Dec 18
David Kelly
EntityIndividual
Role
Member of the Board of Directors
Shares10,000
Max PriceUS$6.29
BuyUS$353,80001 Nov 18
Arix Bioscience plc
EntityCompany
Shares58,000
Max PriceUS$6.10
BuyUS$5,00006 Sep 18
Michael Dunne
EntityIndividual
Role
Chief Scientific Officer
Shares500
Max PriceUS$10.00
BuyUS$10,00028 Aug 18
Michael Dunne
EntityIndividual
Role
Chief Scientific Officer
Shares1,000
Max PriceUS$10.00
BuyUS$5,21927 Aug 18
Paul Edick
EntityIndividual
Shares500
Max PriceUS$10.44

Ownership Breakdown


Management Team

  • Corey Fishman (54yo)

    President

    • Tenure: 3.8yrs
    • Compensation: $1.76m
  • Mike Dunne (59yo)

    Chief Scientific Officer

    • Tenure: 3.8yrs
    • Compensation: $1.15m
  • Judy Matthews (49yo)

    Chief Financial Officer

    • Tenure: 3.8yrs
    • Compensation: $611.66k
  • Ben Pe

    Vice President of Operations

    • Tenure: 4.6yrs
  • Louise Barrett

    Secretary


Board Members

  • Brent K. Ahrens (56yo)

    Interim Chairman

    • Tenure: 0.2yrs
    • Compensation: $105.77k
  • Patrick Heron (49yo)

    Director

    • Tenure: 3.8yrs
    • Compensation: $103.65k
  • Ron Hunt (54yo)

    Director

    • Tenure: 3.8yrs
    • Compensation: $110.93k
  • Mohammed Shahzad Malik (52yo)

    Director

    • Tenure: 2.3yrs
    • Compensation: $107.29k
  • Jim Healy (54yo)

    Director

    • Tenure: 3.8yrs
    • Compensation: $104.86k
  • David Kelly (58yo)

    Director

    • Tenure: 3.0yrs
    • Compensation: $120.53k
  • Corey Fishman (54yo)

    President

    • Compensation: $1.76m
  • Mark Chin (37yo)

    Director

    • Tenure: 2.3yrs
    • Compensation: $109.41k

Company Information

Iterum Therapeutics plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Iterum Therapeutics plc
  • Ticker: ITRM
  • Exchange: NasdaqGM
  • Founded: 2015
  • Industry: pharmaceuticals
  • Sector: pharmaceuticals & biotech
  • Market Cap: US$97.509m
  • Shares outstanding: 14.42m
  • Website: Click here

Number of Employees


Location

  • Iterum Therapeutics plc
  • Harcourt Centre
  • Block 2, Floor 3
  • Dublin
  • Co. Dublin
  • 2
  • Ireland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ITRMNasdaqGM (Nasdaq Global Market)YesOrdinary SharesUSUSDMay 2018

Biography

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulope ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/18 01:14
End of Day Share Price2019/08/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.